His appointment to this newly-created position will support SELLAS' strategy to optimally develop its novel agent, galinpepimut-S immunotherapeutic, which targets the WT1 antigen and has the potential to target more than 25 cancer types. “We are delighted to have attracted a highly regarded analyst to SELLAS' executive team.

His appointment to this newly-created position will support SELLAS' strategy to optimally develop its novel agent, galinpepimut-S immunotherapeutic, which targets the WT1 antigen and has the potential to target more than 25 cancer types. “We are delighted to have attracted a highly regarded analyst to SELLAS' executive team.